AR122359A1 - Formulaciones de fgf-21 conjugado - Google Patents
Formulaciones de fgf-21 conjugadoInfo
- Publication number
- AR122359A1 AR122359A1 ARP210100034A ARP210100034A AR122359A1 AR 122359 A1 AR122359 A1 AR 122359A1 AR P210100034 A ARP210100034 A AR P210100034A AR P210100034 A ARP210100034 A AR P210100034A AR 122359 A1 AR122359 A1 AR 122359A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgf
- conjugate
- formulation
- formulations
- chelator
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 7
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Formulaciones farmacéuticas que comprenden FGF-21 PEGilado, un conjugado de FGF-21, y uno o más estabilizantes tal como DPTA quelante. Las formulaciones pueden ser además estabilizadas mediante la inclusión de un agente tensoactivo tal como polisorbato 80 y/o el ajuste del pH hasta aproximadamente 7,1. También métodos de manufactura, métodos de tratamiento, y kits. Reivindicación 1: Una formulación farmacéutica que comprende (i) un polipéptido conjugado de factor de crecimiento de fibroblasto 21 (FGF-21) a una mitad de polietilénglicol (PEG) (conjugado de FGF-21) y (ii) un quelante de catión de ácido aminopolicarboxílico, en donde la formulación tiene estabilidad mejorada comparado con una formulación de referencia que no contiene el quelante de catión de ácido aminopolicarboxílico, en donde el conjugado de FGF-21 comprended la fórmula (1), y en donde n es cualquier entero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958580P | 2020-01-08 | 2020-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122359A1 true AR122359A1 (es) | 2022-09-07 |
Family
ID=74572842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100034A AR122359A1 (es) | 2020-01-08 | 2021-01-07 | Formulaciones de fgf-21 conjugado |
Country Status (13)
Country | Link |
---|---|
US (2) | US20220016211A1 (es) |
EP (1) | EP4087612A1 (es) |
JP (1) | JP2023510268A (es) |
KR (1) | KR20220125289A (es) |
CN (1) | CN115243725A (es) |
AR (1) | AR122359A1 (es) |
AU (1) | AU2021205912A1 (es) |
BR (1) | BR112022013172A2 (es) |
CA (1) | CA3167062A1 (es) |
IL (1) | IL294534A (es) |
MX (1) | MX2022008336A (es) |
TW (1) | TW202140074A (es) |
WO (1) | WO2021142143A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023538533A (ja) * | 2020-08-07 | 2023-09-08 | ブリストル-マイヤーズ スクイブ カンパニー | 線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21 |
US20240123031A1 (en) * | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
PT1232264E (pt) | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Gene fgf-21 humano e produtos da expressão do gene |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
CA2468610A1 (en) | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
SI1641483T1 (sl) | 2003-06-12 | 2008-08-31 | Lilly Co Eli | Fuzijski proteini |
EP2270163A1 (en) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
US20090111742A1 (en) | 2004-01-26 | 2009-04-30 | Alexei Kharitonenkov | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合fgf−21化合物 |
PT1751184E (pt) | 2004-05-13 | 2009-11-10 | Lilly Co Eli | Proteínas de fusão de fgf-21 |
EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
ES2332057T3 (es) | 2004-09-02 | 2010-01-25 | Eli Lilly And Company | Muteinas del factor de crecimiento de fibroblastos 21. |
HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
EP1831371A2 (en) | 2004-12-14 | 2007-09-12 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
WO2008121563A2 (en) | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
MX2013005075A (es) * | 2010-11-05 | 2013-05-28 | Pfizer | Compuestos antidiabeticos. |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子21蛋白質 |
US9434788B2 (en) | 2012-07-11 | 2016-09-06 | The United States Of America, As Represented By The Secretary Of Agriculture | Bio-based fiber gums (BFGs) and processes for producing BFGs |
JP6423852B2 (ja) * | 2013-03-13 | 2018-11-14 | イーライ リリー アンド カンパニー | 修飾されたイヌレプチンポリペプチド |
MX2017004947A (es) | 2014-10-24 | 2017-06-29 | Bristol Myers Squibb Co | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. |
CN114903978A (zh) * | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
-
2021
- 2021-01-07 CN CN202180018382.9A patent/CN115243725A/zh active Pending
- 2021-01-07 WO PCT/US2021/012530 patent/WO2021142143A1/en active Application Filing
- 2021-01-07 IL IL294534A patent/IL294534A/en unknown
- 2021-01-07 AU AU2021205912A patent/AU2021205912A1/en active Pending
- 2021-01-07 KR KR1020227026861A patent/KR20220125289A/ko unknown
- 2021-01-07 CA CA3167062A patent/CA3167062A1/en active Pending
- 2021-01-07 US US17/143,938 patent/US20220016211A1/en not_active Abandoned
- 2021-01-07 TW TW110100686A patent/TW202140074A/zh unknown
- 2021-01-07 JP JP2022541986A patent/JP2023510268A/ja active Pending
- 2021-01-07 US US17/791,341 patent/US20230346957A1/en active Pending
- 2021-01-07 BR BR112022013172A patent/BR112022013172A2/pt not_active Application Discontinuation
- 2021-01-07 MX MX2022008336A patent/MX2022008336A/es unknown
- 2021-01-07 AR ARP210100034A patent/AR122359A1/es unknown
- 2021-01-07 EP EP21704336.3A patent/EP4087612A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220016211A1 (en) | 2022-01-20 |
MX2022008336A (es) | 2022-08-08 |
BR112022013172A2 (pt) | 2022-09-13 |
TW202140074A (zh) | 2021-11-01 |
CN115243725A (zh) | 2022-10-25 |
AU2021205912A1 (en) | 2022-07-28 |
US20230346957A1 (en) | 2023-11-02 |
EP4087612A1 (en) | 2022-11-16 |
KR20220125289A (ko) | 2022-09-14 |
CA3167062A1 (en) | 2021-07-15 |
IL294534A (en) | 2022-09-01 |
WO2021142143A1 (en) | 2021-07-15 |
JP2023510268A (ja) | 2023-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122359A1 (es) | Formulaciones de fgf-21 conjugado | |
ES2620413T3 (es) | Formulaciones veterinarias antihelmínticas tópicas | |
AU764626B2 (en) | Pharmaceutical formulations of taxanes | |
ES2263450T3 (es) | Preparaciones de g-csf estabilizadas a largo plazo. | |
ES2160693T3 (es) | Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona. | |
KR940008681A (ko) | 디클로페낙 염용 비경구 용액 | |
IT1247529B (it) | Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale | |
DE602005002653D1 (de) | Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid | |
AR029941A1 (es) | Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen | |
ES2325506T3 (es) | Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones. | |
UY27378A1 (es) | Composición farmacéutica | |
SE8304920L (sv) | Farmakologiska kompositioner baserade pa cisplatina och forfarande for framstellning derav | |
ATE404176T1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
PE20011223A1 (es) | Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico | |
AR123570A1 (es) | Tratamientos para el edema macular diabético y la agudeza visual disminuida | |
KR100878198B1 (ko) | 미녹시딜을 포함하는 겔 조성물 | |
MX9400801A (es) | Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon. | |
AR119974A1 (es) | Composición radiofarmacéutica concentrada, estable | |
DK1377164T3 (da) | Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo | |
HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja | |
EP3236938B1 (en) | Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol | |
PE20210632A1 (es) | Formulaciones de fgf-21 | |
CO5540279A2 (es) | Formulacion liofilitada de 2-metil-tieno-benzodiazepina | |
JPWO2014119643A1 (ja) | 澄明な水性液剤 |